Loading stock data…
BridgeBio Oncology Therapeutics (BBOT)
$8.86-0.12 (-1.34%)
Market ClosedLast close Sep 8
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BridgeBio Oncology Therapeutics, Inc. in the Healthcare sector is trading at $8.86 with a market capitalization of $605M. Wall Street consensus targets $24.90 (10 analysts), implying a +181.0% move over the next 12 months. The stock is currently 40% below its 52-week high of $14.87, remaining 9.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +181.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.18M↓ | -$43.41M↑ | -$49.18M↓ | -$30.09M↓ | -$23.14M |
| Net Income | -$42.11M↓ | -$38.80M↑ | -$44.76M↓ | -$28.43M↓ | -$22.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. Th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$605.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-41.39%
Volume
Today's trading volume
152,344
Recent News
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is one of the most promising stocks on our list. TheFly reported on June 22 that Oppenheimer initiated coverage of BBOT with an Outperform rating and a $22 price target. The firm highlighted the company’s […]
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
This clinical-stage biotech develops antibody therapies for severe autoimmune diseases, targeting rare neuromuscular conditions.
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
This clinical-stage biotech targets RAS/MAPK pathway cancers with a pipeline of novel small molecule oncology therapies.
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.